Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference

Rhea-AI Summary

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced that Dr. Henry Ji, its Chairman and CEO, will present at the Evercore ISI 4th Annual HealthCONx Conference scheduled for December 1, 2021, from 3:30 PM to 3:50 PM EST. A registration link is available for attendees. The company focuses on developing therapies for cancer, pain management, autoimmune disease, and COVID-19, utilizing advanced platforms like fully human antibodies and antiviral therapies. An updated corporate presentation will also be accessible on their website.

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference:

• Evercore ISI 4th Annual HealthCONx Conference
  Wednesday, December 1, 2021 at 3:30-3:50 PM EST (Track 3)
  
  Registration link: 4th Annual Evercore ISI HealthCONx Conference (wsw.com)

An updated corporate presentation will be available at www.sorrentotherapeutics.com.

About Sorrento Therapeutics, Inc. 

Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the developments of and expectations for Sorrento's and its subsidiaries’ and affiliates’ products and technologies. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries' technologies and prospects; risks related to seeking regulatory approvals and conducting clinical trials; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020, as amended, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations Contact
Dorman Followwill
Email: mediarelations@sorrentotherapeutics.com

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVISTIX™ are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

©2021 Sorrento Therapeutics, Inc. All Rights Reserved.

FAQ

What is the date and time of Sorrento Therapeutics' conference presentation?

Dr. Henry Ji will present at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, from 3:30 PM to 3:50 PM EST.

Where can I find the registration link for the Evercore ISI HealthCONx Conference?

The registration link for the Evercore ISI HealthCONx Conference is available at wsw.com.

What key therapies is Sorrento Therapeutics currently developing?

Sorrento Therapeutics is developing therapies for cancer, non-opioid pain management, autoimmune diseases, and COVID-19, utilizing various advanced therapeutic platforms.

Where can I access Sorrento Therapeutics' updated corporate presentation?

The updated corporate presentation from Sorrento Therapeutics can be accessed on their official website at sorrentotherapeutics.com.

What is the stock symbol for Sorrento Therapeutics?

The stock symbol for Sorrento Therapeutics is SRNE.